Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial

Richard E. Pratley, Adie Viljoen, J Lüdemann et al.|The Lancet Diabetes & Endocrinology|2018

Cited by 758